Assertio Holdings Inc
ASRT
View Detailed Chart
0.904USD
-0.070-7.22%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
87.01MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-7.22%
5 Days
+11.19%
1 Month
+15.27%
6 Months
+27.38%
Year to Date
+3.81%
1 Year
-33.01%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated: 2025-09-19Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
4
analysts
Buy
Current Rating
2.688
Target Price
+175.73%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).
Undervalued
The company’s latest PE is -2.00, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 28.52M shares, decreasing 51.97% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 4.38M shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).
Ticker SymbolASRT
CompanyAssertio Holdings Inc
CEOMr. Brendan P. O'Grady
Websitehttps://www.assertiotx.com/
Related Instruments
-1.40%
+1.17%
+0.19%
+0.48%
-1.02%
-0.71%
-0.04%
+3.47%
+0.41%
-0.50%
-0.08%
-1.03%
-1.29%
+1.22%
+0.92%
-0.92%
-0.23%
-0.83%
-1.12%
+0.31%
